Brief: MAIA Biotechnology Holds Successful Pre-IND Meeting With FDA For Planned U.S. Expansion Of Thio-101 Phase 2 Trial

Maia Biotechnology

20/12/2022 13:05

Dec 20 (Reuters) - Maia Biotechnology Inc  MAIA.A :
    * MAIA BIOTECHNOLOGY HOLDS SUCCESSFUL PRE-IND MEETING WITH
FDA FOR
PLANNED US EXPANSION OF THIO-101 PHASE 2 TRIAL FOR NON-SMALL
CELL LUNG CANCER
    * MAIA BIOTECHNOLOGY INC- PLANS TO FILE ITS U.S. IND IN
FIRST HALF
OF 2023
    * MAIA BIOTECHNOLOGY INC-  PLANS TO COMMENCE ENROLLING
PATIENTS IN
U.S. IN SECOND HALF OF 2023

Source text for Eikon:  ID:nBw6sQTGfa 
Further company coverage:  MAIA.A 
 ((Reuters.Briefs@thomsonreuters.com;))